Untreated Metastatic or Unresectable Melanoma Pipeline Insight, 2026
The Untreated Metastatic or Unresectable Melanoma pipeline encompasses 10+ companies and 10+ pipeline drugs at various stages of clinical and nonclinical development. The report covers pipeline drug profiles, therapeutics assessment by product type, stage, route of administration, and molecule type, and highlights inactive pipeline products in this space. With clinical-stage assets spanning Phase I through Phase III, and emerging modalities including targeted alpha-particle therapy, therapeutic cancer vaccines, and personalized neoantigen T cell therapies, the pipeline reflects a dynamic and rapidly evolving treatment landscape.
Untreated Metastatic or Unresectable Melanoma Disease Understanding
Untreated Metastatic or Unresectable Melanoma: Overview
Metastatic or unresectable melanoma is an advanced stage of skin cancer where malignant cells have spread from the primary site to other parts of the body or cannot be surgically removed. Melanoma originates in melanocytes, the cells responsible for producing melanin, the pigment that gives skin its color. When melanoma progresses to a metastatic or unresectable stage, it significantly impacts prognosis and requires a more complex treatment approach.
The signs and symptoms of metastatic melanoma vary depending on the organs involved. Common symptoms include persistent skin changes such as new growths, sores that do not heal, and changes in existing moles in size, shape, color, or texture. Symptoms specific to metastasis may include swollen lymph nodes, weight loss, fatigue, bone pain or tenderness, persistent cough or trouble breathing, and neurological symptoms if the brain is affected.
The primary cause of melanoma is DNA damage to melanocytes, often due to ultraviolet radiation from sunlight or tanning beds. Genetic predispositions also play a significant role, with mutations in the BRAF gene present in approximately 50% of melanomas, leading to uncontrolled cell growth. As the cancer advances, malignant cells detach from the primary tumor, invade surrounding tissues, and spread through the lymphatic system or bloodstream to distant organs, often leading to immune evasion and further disease progression.
Download the full pipeline report to explore in-depth drug profiles, clinical trial details, and competitive landscape for Untreated Metastatic or Unresectable Melanoma.
Untreated Metastatic or Unresectable Melanoma Recent Developments
- In April 2025, Perspective Therapeutics announced the dosing of the first patient in a new cohort of a Phase I/IIa trial evaluating the safety of [212Pb]VMT01, a targeted alpha-particle therapy, as monotherapy in patients with histologically confirmed melanoma and positive melanocortin 1 receptor imaging scans. Patients in this cohort are receiving [212Pb]VMT01 at 1.5 mCi as monotherapy
- In March 2025, Perspective Therapeutics announced the dosing of the first patient in a new cohort of the same Phase I/IIa trial, evaluating [212Pb]VMT01 at 1.5 mCi in combination with nivolumab, a PD-1 blocking antibody developed and marketed by Bristol Myers Squibb as Opdivo
- In December 2024, Immuneering Corporation announced that the US FDA granted Fast Track designation to its lead clinical-stage program, IMM-1-104, for the treatment of patients with unresectable or metastatic NRAS-mutant melanoma who have progressed on or are intolerant to PD-1/PD-L1 based immune checkpoint inhibitors
Untreated Metastatic or Unresectable Melanoma Emerging Drugs
- Prolgolimab – Biocad
Prolgolimab is an IgG1 anti-PD-1 monoclonal antibody containing the Fc-silencing LALA mutation, designed to restore the anti-tumor activity of the human body’s immune response. The Ministry of Health of the Russian Federation has authorized a Russian originator drug combining nurulimab and prolgolimab in a 1:3 fixed dose combination of anti-CTLA-4 and anti-PD-1 monoclonal antibodies, marketed under the trade name Nurdati. This combination promotes T cell activation at various stages of the immune response, enabling recognition and destruction of malignant cells. Currently, prolgolimab is in Phase III development for the treatment of unresectable metastatic melanoma, representing the most advanced pipeline asset identified in this report.
- UV1 – Ultimovacs ASA
UV1 is an off-the-shelf therapeutic cancer vaccine designed to induce a specific T cell response against telomerase. It consists of long synthetic peptides representing a sequence in the reverse transcriptase subunit of telomerase, shown to induce CD4+ T cells that provide inflammatory signals and T cell support critical for triggering a strong anti-tumor immune response. UV1 peptides contain several epitopes shown to be non-restrictive in terms of HLA alleles for presentation, removing the requirement for HLA pre-screening and enabling broad population utilization. The vaccine is administered over three months with eight intradermal injections alongside the immune-modulator GM-CSF. In February 2024, the US FDA granted Fast Track designation to UV1 in combination with ipilimumab and nivolumab for unresectable malignant pleural mesothelioma. UV1 is currently in Phase II development for the treatment of unresectable metastatic melanoma.
- ANV419 – Anaveon AG
ANV419 is a powerful and selective IL-2 agonist specifically designed to enable the delivery of high-dose IL-2 to patients with solid tumors, with a favorable safety and tolerability profile. As of the data cut-off of March 31, 2023, 40 adult patients with advanced solid tumors and progression after one or more previous lines of systemic therapy were enrolled and received at least one dose of ANV419. Monotherapy was delivered as an intravenous infusion once every two weeks at doses up to 364 µg/kg. Drug-related adverse events were manageable, reversible, and responsive to supportive care therapy. ANV419 is currently in Phase II development for the treatment of unresectable or metastatic melanoma.
- BNT221 – BioNTech US Inc.
BNT221 is a personal neoantigen-targeting T cell therapy candidate derived from patients’ peripheral blood cells. The product consists of multiple CD8+ and CD4+ T cell populations targeting multiple selected neoantigens unique to each patient’s tumor, with a proprietary stimulation process enabling induction of T cells from the naïve compartment as well as expansion from the memory compartment of the immune system. BNT221 is currently being evaluated in a first-in-human Phase I trial in patients with advanced unresectable or metastatic melanoma. Initial results show a manageable safety profile with no dose-limiting toxicities and tumor regression in several patients with anti-PD-1 and anti-CTLA-4 pretreated advanced or metastatic melanoma.
Find out more about untreated metastatic or unresectable melanoma drugs in the full Pipeline Report.
Untreated Metastatic or Unresectable Melanoma: Therapeutic Assessment
The therapeutic assessment segment of the pipeline report provides structured insights into drug candidates across the following analytical parameters:
Major Players
Approximately 10+ key companies are developing therapies for untreated metastatic or unresectable melanoma. The company with a drug candidate in the most advanced stage – Phase III – is Biocad, with prolgolimab in combination with nurulimab.
Phases
The pipeline encompasses candidates across the full development spectrum, including late-stage products in Phase III, mid-stage products in Phase II, early-stage products in Phase I, and preclinical and discovery-stage candidates, along with discontinued and inactive candidates.
Route of Administration
Pipeline products have been categorized across various routes of administration, including oral, intravenous, subcutaneous, parenteral, and topical delivery.
Molecule Type
Products span multiple molecule types, including recombinant fusion proteins, small molecules, monoclonal antibodies, peptides, polymers, and gene therapies.
Product Type
Drugs have been categorized as mono, combination, or mono/combination product types, reflecting the breadth of treatment strategies under investigation.
Untreated Metastatic or Unresectable Melanoma Pipeline Outlook
The pipeline for untreated metastatic or unresectable melanoma is entering a period of meaningful clinical advancement, supported by expanding immunotherapy combinations, novel radiopharmaceutical approaches, personalized cell therapy strategies, and therapeutic cancer vaccines targeting telomerase. Regulatory recognition through Fast Track designations – awarded to both UV1 and IMM-1-104 – underscores the unmet need in this indication and the clinical promise of emerging candidates. The presence of Phase III assets alongside a broad early-stage pipeline signals a healthy and competitive development landscape with multiple near-term and longer-term opportunities to improve outcomes for patients with this aggressive disease.
Key pipeline figures:
- Approximately 10+ companies and 10+ drug candidates are active in the untreated metastatic or unresectable melanoma pipeline
- Phase III assets include prolgolimab in combination with nurulimab, developed by Biocad
- Phase II assets include UV1 (Ultimovacs ASA) and ANV419 (Anaveon AG)
- Phase I assets include BNT221 (BioNTech), a personalized neoantigen T cell therapy
- The FDA has granted Fast Track designation to UV1 (in combination with ipilimumab and nivolumab) and IMM-1-104 (for NRAS-mutant melanoma), highlighting regulatory alignment with pipeline priorities
- Targeted alpha-particle therapy [212Pb]VMT01 (Perspective Therapeutics) is actively enrolling new cohorts in Phase I/IIa as both monotherapy and in combination with nivolumab
Request a free sample today and unlock comprehensive insights driving the Untreated Metastatic or Unresectable Melanoma pipeline landscape.
Conclusion
The untreated metastatic or unresectable melanoma pipeline is advancing on multiple therapeutic fronts, with immuno-oncology combinations, personalized cell therapies, therapeutic cancer vaccines, and targeted radiopharmaceuticals all representing active areas of clinical investigation. The pipeline encompasses approximately 10+ companies and 10+ drug candidates at various stages of development, with Biocad’s prolgolimab-nurulimab combination representing the most advanced Phase III asset. Strategic regulatory designations, active first-in-human trials, and a growing body of early clinical data collectively signal a promising trajectory toward improved treatment options for patients with this high-unmet-need indication. As the field continues to evolve – driven by molecular stratification, combination approaches, and next-generation modalities – the pipeline is well-positioned to deliver meaningful advances in outcomes for patients with untreated metastatic or unresectable melanoma across global geographies.
About DelveInsight
DelveInsight is a leading Healthcare Business Consultant and Market Research firm focused exclusively on life sciences. It supports pharmaceutical companies by providing comprehensive end-to-end solutions to improve their performance. It also offers healthcare consulting services that leverage market analysis to accelerate business growth and overcome challenges with practical approaches.
Media contact
Name: Abhishek kumar
E-mail: abhishek@delveinsight.com
